![](https://webarchive.library.unt.edu/eot2008/20081003205638im_/http://www.nci.nih.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20081003205638im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081003205638im_/http://www.nci.nih.gov/images/spacer.gif)
| A monoclonal antibody being studied in the treatment of certain types of B-cell cancers including chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin lymphoma. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. HuMax-CD20 binds to CD20, a protein on the surface of normal B cells and most B-cell tumors. Also called ofatumumab. |
![](https://webarchive.library.unt.edu/eot2008/20081003205638im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081003205638im_/http://www.nci.nih.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081003205638im_/http://www.nci.nih.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081003205638im_/http://www.nci.nih.gov/images/spacer.gif) |